Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine Hydrochloride for Prevention of Irinotecan-Induced Diarrhea in Solid Tumors
ChiCTR2600124144Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Zhejiang Chinese Medical University
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Non-hematologic malignancy comparing Berberine Hydrochloride Tablets with Placebo (2 arms). Primary endpoint: Incidence of Grade ≥2 Diarrhea. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
berberine
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR2600124144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124144.